Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma

Click here for the corresponding questions to this CME article.

Saved in:
Bibliographic Details
Published inClinical and experimental dermatology Vol. 44; no. 5; pp. 562 - 564
Main Authors Wolf, S., Goiriz, R., Dhairyawan, R., Paige, D., Rizvi, H., Haroon, A., Montoto, S.
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.07.2019
Subjects
Anaplastic large-cell lymphoma
Antineoplastic Agents, Immunological - therapeutic use
Brentuximab Vedotin - therapeutic use
Diagnosis, Differential
HIV
HIV Infections - complications
Hodgkin Disease - complications
Hodgkin's lymphoma
Human immunodeficiency virus
Humans
Immunotherapy
Lymphoma
Lymphoma, Large-Cell, Anaplastic - complications
Lymphoma, Large-Cell, Anaplastic - diagnosis
Lymphoma, Large-Cell, Anaplastic - drug therapy
Lymphoma, Large-Cell, Anaplastic - pathology
Male
Middle Aged
Monoclonal antibodies
Skin - pathology
Skin Neoplasms - complications
Skin Neoplasms - diagnosis
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Summary:Click here for the corresponding questions to this CME article.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.13824